Tyrosine kinase inhibitors (TKIs) targeting the BCR-ABL1 fusion protein, encoded by the 22 Philadelphia chromosome, have drastically improved the outcomes for patients with 23 chronic myeloid leukemia (CML). Although several real-time quantitative polymerase 24 chain reaction (RQ-PCR) kits for the detection of BCR-ABL1 transcripts are 25 commercially available, their accuracy and efficiency in laboratory practice require 26 reevaluation. We have developed a new in-house RQ-PCR method to detect minimal 27 residual disease (MRD) in CML cases. MRD was analyzed in 102 patients with CML 28 from the DOMEST study, a clinical trial to study the rationale for imatinib mesylate 29 discontinuation in Japan. The BCR-ABL1/ABL1 ratio was evaluated using the 30 international standard (IS) ratio, where IS < 0.01% was defined as a major molecular 31 response. At enrollment, BCR-ABL1 transcripts were undetectable in all samples using a 32 widely-applied RQ-PCR method performed in the commercial laboratory, BML (BML 33
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Introduction is caused by a reciprocal translocation between chromosomes 9 and 22 Graduate School of Medicine. All participants provided written informed consent for their 118 samples and data from their medical records to be used for research. 119 In the DOMEST study, RQ-PCR was performed every month for the first year and 120 every 3 months for the second year by BML (16, 25) ; molecular recurrence was defined 121 as BCR-ABL1 detected by two successive tests, or by loss of MR3.0 in one test. Residual 122 total RNA samples from the study were subsequently used for measurement using the in-123 house RQ-PCR method. The major BCR-ABL1 mRNA assay kit, ODK-1201 
Results

199
Background of patients 200 Between January 2014 and May 2015, a total of 110 patients were enrolled for the 201 DOMEST study; 104 of them were evaluated in this study. Among these patients, 102 202 were confirmed as having DMR (MR4.0) status, defined as "BCR-ABL1 transcript levels 203 below the detection limit of the widely-used BML method." After MR4.0 (Log4) was 204 confirmed, imatinib was ceased. The other two patients were excluded from this study 205 because BCR-ABL1 transcripts were detected at enrollment, and dasatinib was started.
206
Patient characteristics are summarized in Table 1 . at an average ± standard deviation of 2.47 ± 2.13 months after cessation of imatinib 221 (concordant cases, Table 2 ). In one case (patient #15), the fusion transcript level was < 222 0.01% by the BML method. In these recurred cases, TKI therapies were restarted in the 223 DOMEST study.
224 225 S1 By contrast, the results were discordant between the in-house and BML methods in In conclusion, our newly developed in-house RQ-PCR method with IS calibration 298 was accurate and effective for detecting MRD in the context of an imatinib cessation 299 study. The main advantages of this assay lie in the promptness with which results are
